- Home
- ONB vs LEGN Comparison
ONB vs LEGN Comparison
Compare ONB & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONB
- LEGN
- Stock Information
- Founded
- ONB 1834
- LEGN 2014
- Country
- ONB United States
- LEGN United States
- Employees
- ONB N/A
- LEGN N/A
- Industry
- ONB Major Banks
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- ONB Finance
- LEGN Health Care
- Exchange
- ONB Nasdaq
- LEGN Nasdaq
- Market Cap
- ONB 7.6B
- LEGN 5.4B
- IPO Year
- ONB N/A
- LEGN 2020
- Fundamental
- Price
- ONB $23.16
- LEGN $38.96
- Analyst Decision
- ONB Buy
- LEGN Strong Buy
- Analyst Count
- ONB 10
- LEGN 12
- Target Price
- ONB $26.50
- LEGN $73.91
- AVG Volume (30 Days)
- ONB 3.1M
- LEGN 1.6M
- Earning Date
- ONB 07-22-2025
- LEGN 08-08-2025
- Dividend Yield
- ONB 2.42%
- LEGN N/A
- EPS Growth
- ONB N/A
- LEGN N/A
- EPS
- ONB 1.72
- LEGN N/A
- Revenue
- ONB $1,795,802,000.00
- LEGN $728,303,000.00
- Revenue This Year
- ONB $44.53
- LEGN $65.49
- Revenue Next Year
- ONB $16.14
- LEGN $53.76
- P/E Ratio
- ONB $13.48
- LEGN N/A
- Revenue Growth
- ONB 3.29
- LEGN 112.46
- 52 Week Low
- ONB $16.83
- LEGN $27.34
- 52 Week High
- ONB $24.49
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- ONB 66.95
- LEGN 66.26
- Support Level
- ONB $22.44
- LEGN $34.64
- Resistance Level
- ONB $23.61
- LEGN $39.88
- Average True Range (ATR)
- ONB 0.50
- LEGN 1.46
- MACD
- ONB 0.21
- LEGN 0.37
- Stochastic Oscillator
- ONB 86.36
- LEGN 87.67
About ONB Old National Bancorp
Old National Bancorp with almost $10 billion in assets following its latest acquisition, Old National Bancorp is a financial services bank holding company headquartered in Indiana. Based in Evansville, Ind., Old National owns multiple financial services operations in Indiana, Illinois, and Kentucky. The company provides a group of similar community banking services, including such products and services as commercial, real estate, and consumer loans; deposits; and brokerage, trust, and investment advisory services.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.